Melanoma in the brain: steroids plus targeted therapy
Part of Brain & nervous system, Cancer, Skin clinical trials.
This Phase 2 trial studies how giving steroid medicine for brain swelling may help people with melanoma that has spread to the brain, and whether adding a targeted approach works for a specific genetic tumor type. It may help shrink brain tumors and improve symptoms, while comparing how patients respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma that has spread to the brain, confirmed by scan and biopsy (histology).
- You must be able to take steroid medicine to control brain swelling, at the required dose range.
- You need at least one measurable brain tumor spot on scan, and the brain disease must be assessable by doctors.
- You must be 18 or older and well enough to participate (performance status 0–2).
- You must be able to have an MRI with contrast dye called gadolinium.
- Your tumor must have no recent major treatment problems and you must be able to give consent and follow study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug that stops blood vessel growth (bevacizumab), immunotherapy, and focused radiation to treat melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial studies whether giving the immunotherapy drug nivolumab together with targeted brain radiation (not whole-brain radiation) helps people with melanoma that has spread to the brain. It aims to improve brain control while keeping side effects manageable.
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
Hear when a new Malignant Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.